Pharma News

Novartis announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective low-density lipoprotein cholesterol (LDL-C) reduction over a four-year period in patients with either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-C despite maximally tolerated statin therapy.

Viatris intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.

The costliness of drug development and the limitations of studying physiological processes in the lab are two separate scientific issues that may share the same solution.

New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure (HF) and mildly reduced or preserved ejection fraction (EF) compared with placebo1. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois, US, and are currently in press in the Journal of the American College of Cardiology.

Pioneering artificial intelligence (AI) which automatically diagnoses lung diseases – such as tuberculosis and pneumonia – could ease winter pressures on hospitals, University of the West of Scotland researchers believe.

Tuberculosis and pneumonia – potentially serious infections which mainly affect the lungs – often require a combination of different diagnostic tests – such as CT scans, blood tests, X-rays, and ultrasounds. These tests can be expensive, with often lengthy waiting times for results.

Pfizer Inc announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb).

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.

RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two.

Indian Pharmacopoeia Commission clarifies on three new general chapters introduced in Indian Pharmacopoeia 2022 which are on Uniformity of Dosage Units, Elemental Impurities and Nitrosamine Impurities.

Indian Pharmacopoeia Commission (IPC) has published the Indian Pharmacopoeia (IP) 2022 and Hon ble Union Health Minister released the 9th edition of IP 2022 in July, 2022 in Vigyan Bhawan. New Delhi.

In-Cosmetics Asia 2022 Exhibition & Conference was held in Bangkok, Thailand from 1st to 3rd November 2022. It is regarded as an annual meeting hub for the Asia Pacific cosmetic and personal care industry, bringing together exhibiting ingredient suppliers and visiting manufacturers keen to source ingredients, learn, network and do business. This is where all areas of the cosmetics industry connect to inspire, share insights and spark potential collaborations.